Clinical improvement in psoriasis with specific targeting of interleukin-23
- 9 March 2015
- journal article
- research article
- Published by Springer Nature in Nature
- Vol. 521 (7551) , 222-226
Abstract
Psoriasis is a chronic inflammatory skin disorder that affects approximately 2-3% of the population worldwide and has severe effects on patients' physical and psychological well-being. The discovery that psoriasis is an immune-mediated disease has led to more targeted, effective therapies; recent advances have focused on the interleukin (IL)-12/23p40 subunit shared by IL-12 and IL-23. Evidence suggests that specific inhibition of IL-23 would result in improvement in psoriasis. Here we evaluate tildrakizumab, a monoclonal antibody that targets the IL-23p19 subunit, in a three-part, randomized, placebo-controlled, sequential, rising multiple-dose phase I study in patients with moderate-to-severe psoriasis to provide clinical proof that specific targeting of IL-23p19 results in symptomatic improvement of disease severity in human subjects. A 75% reduction in the psoriasis area and severity index (PASI) score (PASI75) was achieved by all subjects in parts 1 and 3 (pooled) in the 3 and 10 mg kg(-1) groups by day 196. In part 2, 10 out of 15 subjects in the 3 mg kg(-1) group and 13 out of 14 subjects in the 10 mg kg(-1) group achieved a PASI75 by day 112. Tildrakizumab demonstrated important clinical improvement in moderate-to-severe psoriasis patients as demonstrated by improvements in PASI scores and histological samples.Keywords
This publication has 31 references indexed in Scilit:
- Balance of Treg vs. T-helper cells in the transition from symptomless to lesional psoriatic skinBritish Journal of Dermatology, 2013
- Platelet Endothelial Cell Adhesion Molecule-1 (PECAM-1/CD31) and CD99 Are Critical in Lymphatic Transmigration of Human Dendritic CellsJournal of Investigative Dermatology, 2012
- Genetic lessons learned from X‐linked Mendelian susceptibility to mycobacterial diseasesAnnals of the New York Academy of Sciences, 2011
- Clinical and Cytological Effects of Pimecrolimus Cream 1% after Resolution of Active Atopic Dermatitis Lesions by Topical Corticosteroids: A Randomized Controlled TrialDermatology, 2010
- The PKC inhibitor AEB071 may be a therapeutic option for psoriasisJournal of Clinical Investigation, 2008
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)The Lancet, 2008
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)The Lancet, 2008
- IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2–dependent mechanisms with implications for psoriasis pathogenesisJournal of Experimental Medicine, 2006
- Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptidesJournal of Experimental Medicine, 2006
- PsoriasisNew England Journal of Medicine, 2005